BR0316244A - Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo - Google Patents

Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo

Info

Publication number
BR0316244A
BR0316244A BR0316244-3A BR0316244A BR0316244A BR 0316244 A BR0316244 A BR 0316244A BR 0316244 A BR0316244 A BR 0316244A BR 0316244 A BR0316244 A BR 0316244A
Authority
BR
Brazil
Prior art keywords
protein
hcv
methods
polynucleotide vaccine
vaccine
Prior art date
Application number
BR0316244-3A
Other languages
English (en)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0316244A publication Critical patent/BR0316244A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"VACINA DE POLINUCLEOTìDEO, MéTODOS DE PREVENçãO OU DE TRATAMENTO DE UMA INFECçãO POR HCV EM UM MAMìFERO E DE VACINAçãO DE UM INDIVìDUO, E, USO DE UMA VACINA DE POLINUCLEOTìDEO". A presente invenção refere-se aos métodos e às composições úteis no tratamento e na prevenção de infecções por vírus da Hepatite C (HCV) e dos sintomas e das doenças associados com o mesmo. Em particular a presente invenção refere-se às vacinas de DNA que codificam a proteína de núcleo de HCV e a uma seq³ência de polinucleotídeo que codifica pelo menos uma outra proteína de HCV, na qual a vacina causa a expressão das proteínas dentro da mesma célula e a seq³ência da seq³ência de polinucleotídeo codificadora da proteína de núcleo tem sido mutada ou posicionada em relação à seq³ência de polinucleotídeo codificadora de pelo menos uma outra proteína de HCV de tal modo que é reduzido o efeito negativo da expressão da proteína de núcleo sobre a expressão da citada pelo menos uma outra proteína de HCV.
BR0316244-3A 2002-11-15 2003-11-13 Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo BR0316244A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012793 WO2004046175A1 (en) 2002-11-15 2003-11-13 Vaccine

Publications (1)

Publication Number Publication Date
BR0316244A true BR0316244A (pt) 2005-10-04

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316291-5A BR0316291A (pt) 2002-11-15 2003-11-13 Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
BR0316244-3A BR0316244A (pt) 2002-11-15 2003-11-13 Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0316291-5A BR0316291A (pt) 2002-11-15 2003-11-13 Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv

Country Status (21)

Country Link
US (4) US20060135451A1 (pt)
EP (2) EP1560845A1 (pt)
JP (2) JP2006524181A (pt)
KR (2) KR20050085009A (pt)
CN (2) CN1738834A (pt)
AR (1) AR041964A1 (pt)
AU (2) AU2003288072A1 (pt)
BR (2) BR0316291A (pt)
CA (2) CA2504715A1 (pt)
CO (1) CO5700833A2 (pt)
GB (1) GB0226722D0 (pt)
IS (2) IS7830A (pt)
MA (2) MA27700A1 (pt)
MX (2) MXPA05005202A (pt)
NO (2) NO20052149L (pt)
NZ (2) NZ539998A (pt)
PL (2) PL376967A1 (pt)
RU (2) RU2323744C2 (pt)
TW (1) TW200502246A (pt)
WO (2) WO2004046175A1 (pt)
ZA (2) ZA200503803B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
BRPI0708393A2 (pt) * 2006-03-09 2011-05-31 Transgene Sa proteìna de fusão não estrutural do vìrus da hepatite c
JP2009544322A (ja) * 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
WO2008094197A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2009131681A2 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
EP2331123A4 (en) * 2008-07-24 2012-11-07 Aduro Biotech COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
CN102753582A (zh) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
RU2684211C2 (ru) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Композиция вакцины

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
EP0789563B8 (en) * 1994-10-05 2004-11-17 Apollon, Inc. Hepatitis virus b and c vaccines
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
EP1009763A4 (en) * 1996-06-11 2002-08-07 Merck & Co Inc SYNTHETIC GENES OF HEPATITIS C
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
CA2390082C (en) * 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
NO20052149L (no) 2005-07-11
KR20050085009A (ko) 2005-08-29
PL376967A1 (pl) 2006-01-23
AU2003288072A1 (en) 2004-06-15
EP1560844A1 (en) 2005-08-10
ZA200503802B (en) 2006-08-30
RU2363492C2 (ru) 2009-08-10
TW200502246A (en) 2005-01-16
US20090232847A1 (en) 2009-09-17
NZ539999A (en) 2008-03-28
CN1738833A (zh) 2006-02-22
WO2004046176A1 (en) 2004-06-03
CN1738834A (zh) 2006-02-22
KR20050085010A (ko) 2005-08-29
EP1560845A1 (en) 2005-08-10
WO2004046175A1 (en) 2004-06-03
IS7830A (is) 2005-04-28
US20090104231A1 (en) 2009-04-23
AR041964A1 (es) 2005-06-01
CA2504654A1 (en) 2004-06-03
NO20052136D0 (no) 2005-05-02
US20060135451A1 (en) 2006-06-22
RU2323744C2 (ru) 2008-05-10
CO5700833A2 (es) 2006-11-30
MXPA05005202A (es) 2006-01-27
NO20052136L (no) 2005-07-11
JP2006524181A (ja) 2006-10-26
RU2005113691A (ru) 2006-01-27
US20060246090A1 (en) 2006-11-02
PL376882A1 (pl) 2006-01-09
GB0226722D0 (en) 2002-12-24
JP2006518331A (ja) 2006-08-10
MA27700A1 (fr) 2006-01-02
AU2003288084A1 (en) 2004-06-15
RU2005113692A (ru) 2006-01-27
MXPA05005203A (es) 2006-01-27
BR0316291A (pt) 2005-10-11
IS7831A (is) 2005-04-28
MA27699A1 (fr) 2006-01-02
NO20052149D0 (no) 2005-05-02
ZA200503803B (en) 2006-08-30
NZ539998A (en) 2008-04-30
CA2504715A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
DE69837934D1 (de) Multisystemisches kümmerwuchssyndrom durch viren in schweine
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
EE200300173A (et) Vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ja vaktsiin ning meetod immuunreaktsiooni mõjutamiseks
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BR9913157A (pt) Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
BR0014155A (pt) Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino
HUP9903822A2 (hu) Polinukleotid-vakcinakészítmény sertések szaporodásbiológiai és légzőszervi kórképei ellen
MA27292A1 (fr) Procedes et compositions pour le traitement du virus de l'hepatite c
DE60044778D1 (de) Schweine-circovirus-impfstoff in rekombinantem pockenvirus
ES2107609T3 (es) Polipeptidos sinteticos como inhibidores de vih-1.
BR0309339A (pt) Vìrus vaccinia modificado ankara para a vacinação de neonatos
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
BR0206995A (pt) Tratamento do vìrus da hepatite b
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
ES2132330T3 (es) Vacuna para la proteccion de caballos frente a la infeccion por el virus del herpes equino.
BR0203518A (pt) Proteìnas purificadas do envelope do vìrus de hepatite c para uso diagnóstico e terapêutico
BR0108442A (pt) Mutantes-ehv gm-negativos
BR0213554A (pt) Timosina para aumento da imunização genética
CY1116153T1 (el) Ιος συνδρομου πολυσυστηματικης απισχνανσεως μετα τον απογαλακτισμο απο χοιρους
BR112022005967A2 (pt) Uso do agente para indução de imunidade específica contra o vírus da síndrome respiratória aguda grave sars-cov-2 para revacinação da população (variantes)
Spalton et al. Echo 11 conjunctivitis.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.